Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer

Kiewe, Philipp; Hasmüller, Stephan; Kahlert, Steffen; Heinrigs, M; Rack, Brigitte; Marmé, Alexander; Korfel, Agnieszka; Jäger, Michael; Lindhofer, Horst; Sommer, Harald; Thiel, Eckhard; Untch, Michael

doi:10.1158/1078-0432.ccr-05-2436

Public

Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer

Published in Clinical Cancer Research • May 15, 2006

Authors:

Philipp Kiewe

Stephan Hasmüller

Steffen Kahlert

Abstract

PURPOSE: Ertumaxomab is an intact bispecific antibody targeting HER2/neu and CD3 with selective binding to activatory Fcgamma type I/III receptors, resulting in the formation of a tri-cell complex between tumor cells, T cells, and accessory cells. Patients with metastatic breast cancer were enrolled...

Subject

Medicine

Adverse effect

Lymphocytopenia

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!